A*STAR Skin Research Labs (A*STAR SRL)

The identification of a class of inflammatory immune cells offers new opportunities to treat chronic skin conditions.

Researchers discover that the deletion of a gene linked to glucose metabolism leads to smaller pancreatic tumours and better patient survival.

Ushering in an era of targeted precision medicine, scientists across A*STAR are propelling the research, commercialisation and implementation of RNA-based therapeutics.

Nuevocor, an A*STAR spin-off company, is designing novel therapies to target the genetic causes of heart diseases, bringing basic research to clinical impact.